Genlantis (Gene Therapy Systems Inc.) specializes in advanced transfection technologies, offering a range of solutions for DNA and siRNA transfection across various cell types, including neuronal and insect cells. Their product line includes transfection accessories and optimization tools designed for high-throughput applications, ensuring efficient delivery of genetic material into target cells. Additionally, Genlantis provides a variety of cell culture media and reagents, including animal-free options, to support the growth and maintenance of diverse cell lines, such as human, bovine, porcine, and rat cells. They also focus on mycoplasma contamination detection to ensure the integrity of cell cultures.

In the realm of RNA interference (RNAi), Genlantis offers siRNA generation kits and transfection solutions tailored for effective gene silencing. Their portfolio extends to competent cells and protein expression systems, along with reporter vectors and assay kits that facilitate the study of gene expression and protein interactions. Furthermore, Genlantis provides essential tools for proteomics, including protein delivery systems, cell lysis reagents, and protein extraction kits, as well as standards and stains for protein analysis. Overall, Genlantis is committed to supporting researchers with high-quality products that enhance the efficiency and reliability of molecular biology experiments.

United States

Genlantis is a biotechnology company that develops innovative reagents for various research purposes including transfection, gene expression, primary cell culture, and proteomics.

Genlantis (Gene Therapy Systems Inc.)

Company Details